Patent ID: 8188259

Claim:
A composition suitable for administration in a mammal suffering from a pathological disorder or disease comprising at least three modified oligonucleotides, wherein a first, a second, and a third modified oligonucleotide each comprises about seven to seventy-five nucleotides containing seven or more contiguous ribose groups linked by achiral 5′ to 3′ internucleotide phosphate linkages, wherein at least one ribose group of at least one of said modified oligonucleotides has a modified 2′ substituent, wherein the 5′ and 3′ ends of at least one of said modified oligonucleotides are blocked, and wherein said first modified oligonucleotide is complementary to a region of phosphodiesterase 4 (SEQ ID NO: 82); and said second modified oligonucleotide is complementary to a region of phosphodiesterase 5 (SEQ ID NO: 95), and said third modified oligonucleotide is complementary to a region of cyclo-oxygenase 2 (SEQ ID NO: 87).